Eric Wooltorton. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » 3',5'-Cyclic-GMP Phosphodiesterases/antagonists & inhibitorsAtherosclerosis/complicationsCarbolines/adverse effectsCarbolines/therapeutic useErectile Dysfunction/drug therapyHumansImidazoles/adverse effectsImidazoles/therapeutic useMaleOptic Neuropathy, Ischemic/chemically inducedPhosphodiesterase Inhibitors/adverse effectsPhosphodiesterase Inhibitors/therapeutic usePiperazines/adverse effectsPiperazines/therapeutic usePurinesRisk FactorsSildenafil CitrateSulfones/adverse effectsSulfones/therapeutic useTadalafilTriazines/adverse effectsTriazines/therapeutic useVardenafil DihydrochlorideVision Disorders/chemically induced
Substances： See more » CarbolinesImidazolesPhosphodiesterase InhibitorsPiperazinesPurinesSulfonesTriazinesVardenafil DihydrochlorideTadalafilSildenafil Citrate3',5'-Cyclic-GMP Phosphodiesterases
Year: 2006 PMID： 16870715 PMCID： PMC1534090 DOI： 10.1503/cmaj.060935
Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262